Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

NCT00722384 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: bevasiranib
DRUG: bevasiranib

Sponsor

OPKO Health, Inc.